With a focus on PICK1 as a putative target in Alzheimer’s disease, Biogen also identified a series of PICK1 inhibitors, and although affinities down to 69 nM were obtained and the molecule was co-crystalized with the PICK1 PDZ domain (PDB: 6AR4), a further development was abandoned due to poor pharmacokinetic properties, as claimed by the authors [76,77]. Here, PICK1 is linked to Alzheimer disease.